Acute myeloid leukemia is a highly aggressive form of leukemia, and a new review article examines how tiny vesicles shed by platelets may influence its progression and how those same vesicles could be turned into tools for treatment. The review, published in the journal Cancer Nanotechnology, focuses on platelet-derived microparticles, membrane-bound fragments released from activated platelets that circulate in the blood of healthy individuals. According to the authors, these particles account for 70 to 90 percent of the microvesicles found in healthy human blood, making them one of the most abundant vesicle populations in circulation.
The review brings together evidence that cancer cells can affect platelet activation, and that activated platelets may in turn promote the proliferation and metastasis of cancer cells. The authors argue that interactions between platelet-derived microparticles and cancer cells can worsen disease by transferring cargo molecules between the particles and tumor cells. The cargo described in the review includes cytokines, proteins, receptors, microRNA and DNA, a molecular payload capable of altering the behavior of recipient cells.
What makes the review notable is its attention to structure. Rather than treating platelet-derived microparticles as uniform delivery vehicles, the authors set out to investigate the impact of the particles’ structural components separately on the progression of acute myeloid leukemia. The stated aim is to provide a foundation for the design of engineered particles, in which specific structural features are modified to facilitate drug delivery. The authors describe this as an attempt to use what they call the remarkable engineering of nature, adapting biological structures that already navigate the bloodstream.
The review also highlights a less obvious property of these particles. In the tumor microenvironment, platelet-derived microparticles can harbor antitumor functions, meaning their effects on cancer are not exclusively harmful.
Building on that biological groundwork, the review turns to nanotechnology. The broader literature has generally examined the role of these particles in hematological cancers as a class, but the present review specifically concentrates on acute myeloid leukemia, narrowing a diffuse body of work to a single disease.
The culmination of the review is a proposed treatment model. Drawing on previous studies that employed platelet-derived microparticles for the delivery of nanoparticles alongside chemotherapeutic agents in other cancers, the authors propose a model for acute myeloid leukemia that combines chemotherapy with nanoparticles encapsulated within engineered platelet-derived microparticles.
As a review, the article synthesizes prior findings rather than presenting new experimental data, and its conclusions are framed as a design foundation rather than a validated therapy. Whether the proposed model can be realized safely and effectively in acute myeloid leukemia remains a question for future experimental and clinical studies.
Subject of Research: The role of platelet-derived microparticles in acute myeloid leukemia progression and their proposed use as engineered nanoparticle drug delivery carriers
Article Title: The role of platelet-derived microparticles in the progression of acute myeloid leukemia and their application in cancer nanotechnology
Article References: Yazdani, B., Yari, F., & Mohammadi, S. (2026). The role of platelet-derived microparticles in the progression of acute myeloid leukemia and their application in cancer nanotechnology. Cancer Nanotechnology. https://doi.org/10.1186/s12645-026-00440-8
Image Credits: AI Generated
DOI: 10.1186/s12645-026-00440-8
Keywords: acute myeloid leukemia, platelet-derived microparticles, cancer nanotechnology, drug delivery, tumor microenvironment, microvesicles, nanoparticles, chemotherapy, hematological cancers, cytokines, microRNA, leukemia research
News Source: Nathaniel Bowman. (November 5, 2026). Platelet-derived microparticles may drive acute myeloid leukemia progression and inspire nanoparticle drug delivery. Scienmag.
